AxoGen Stock Forecast, Price & News

+0.74 (+3.55 %)
(As of 06/21/2021 03:33 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume4,745 shs
Average Volume243,316 shs
Market Capitalization$884.02 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AxoGen logo

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.50 out of 5 stars

Medical Sector

588th out of 2,101 stocks

Electromedical Equipment Industry

12th out of 61 stocks

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

Is AxoGen a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AxoGen stock.
View analyst ratings for AxoGen
or view top-rated stocks.

What stocks does MarketBeat like better than AxoGen?

Wall Street analysts have given AxoGen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AxoGen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AxoGen?

AxoGen saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,440,000 shares, an increase of 18.0% from the May 13th total of 1,220,000 shares. Based on an average daily trading volume, of 221,600 shares, the days-to-cover ratio is presently 6.5 days. Currently, 3.8% of the shares of the company are sold short.
View AxoGen's Short Interest

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for AxoGen

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Tuesday, May, 4th. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.12. The medical equipment provider earned $31.04 million during the quarter, compared to analysts' expectations of $28.65 million. AxoGen had a negative net margin of 18.69% and a negative trailing twelve-month return on equity of 17.69%.
View AxoGen's earnings history

How has AxoGen's stock price been impacted by Coronavirus?

AxoGen's stock was trading at $10.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXGN stock has increased by 101.5% and is now trading at $21.56.
View which stocks have been most impacted by COVID-19

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $133 million-$136 million, compared to the consensus revenue estimate of $125.70 million.

What price target have analysts set for AXGN?

5 equities research analysts have issued 12 month price objectives for AxoGen's stock. Their forecasts range from $23.00 to $27.00. On average, they anticipate AxoGen's stock price to reach $24.50 in the next year. This suggests a possible upside of 13.6% from the stock's current price.
View analysts' price targets for AxoGen
or view top-rated stocks among Wall Street analysts.

Who are AxoGen's key executives?

AxoGen's management team includes the following people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 59, Pay $1.54M)
  • Mr. Peter J. Mariani, Exec. VP & CFO (Age 57, Pay $795.83k)
  • Mr. Bradley L. Ottinger J.D., Gen. Counsel & Chief Compliance Officer (Age 51, Pay $387.08k)
  • Mr. Angelo G. Scopelianos Ph.D., Chief R&D Officer (Age 66, Pay $695.49k)
  • Mr. Eric A. Sandberg, Chief Commercial Officer (Age 56, Pay $706.62k)
  • Mr. Michael Donovan, VP of Operations (Age 56)
  • Mr. Gregory Davault, VP of Marketing (Age 53)
  • Ms. Maria D. Martinez, Chief HR Officer (Age 53)
  • Ms. Isabelle Billet, Chief Strategy & Bus. Devel. Officer (Age 59)
  • Mr. David Hansen, VP of Fin. & Treasurer (Age 60)

What is Karen Zaderej's approval rating as AxoGen's CEO?

3 employees have rated AxoGen CEO Karen Zaderej on Karen Zaderej has an approval rating of 100% among AxoGen's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.43%), First Light Asset Management LLC (6.24%), William Blair Investment Management LLC (3.57%), Janus Henderson Group PLC (3.35%), Baillie Gifford & Co. (2.87%) and Point72 Asset Management L.P. (1.50%). Company insiders that own AxoGen stock include Angelo Scopelianos, Daniel Pietrzak, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and Quentin S Blackford.
View institutional ownership trends for AxoGen

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Millennium Management LLC, G2 Investment Partners Management LLC, JPMorgan Chase & Co., Janus Henderson Group PLC, Bank of Montreal Can, Ameriprise Financial Inc., and Granite Investment Partners LLC. Company insiders that have sold AxoGen company stock in the last year include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, and Peter J Mariani.
View insider buying and selling activity for AxoGen
or view top insider-selling stocks.

Which major investors are buying AxoGen stock?

AXGN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., First Light Asset Management LLC, Federated Hermes Inc., William Blair Investment Management LLC, Dimensional Fund Advisors LP, Bamco Inc. NY, Calamos Advisors LLC, and Advisory Research Inc.. Company insiders that have bought AxoGen stock in the last two years include Daniel Pietrzak, Isabelle Billet, Karen L Zaderej, and Quentin S Blackford.
View insider buying and selling activity for AxoGen
or or view top insider-buying stocks.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $21.56.

How much money does AxoGen make?

AxoGen has a market capitalization of $884.02 million and generates $112.30 million in revenue each year. The medical equipment provider earns $-23,790,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does AxoGen have?

AxoGen employs 346 workers across the globe.

What is AxoGen's official website?

The official website for AxoGen is

Where are AxoGen's headquarters?

AxoGen is headquartered at 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.